We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
- Authors
Burghaus, Stefanie; Halmen, Sonja; Gass, Paul; Mehlhorn, Grit; Schrauder, Michael; Lux, Michael; Renner, Stefan; Beckmann, Matthias; Hein, Alexander; Thiel, Falk; Schrauder, Michael G; Lux, Michael P; Renner, Stefan P; Beckmann, Matthias W; Thiel, Falk C
- Abstract
<bold>Purpose: </bold>There is low evidence regarding the optimal treatment in patients with uterine sarcomas and malignant mixed Mullerian tumors (MMMTs). This study provides an overview of experience at our center with patients diagnosed with uterine sarcoma and MMMT, in relation to the clinical management and outcome.<bold>Methods: </bold>The medical records for 143 patients with low-grade endometrial stromal sarcoma (ESS), leiomyosarcoma (LMS), and high-grade (undifferentiated) endometrial sarcoma (UES) and MMMT were reviewed. All available clinical and pathological data were collected and analyzed. Putative prognostic factors were entered into a multivariate analysis using a Cox proportional hazards ratio model, and survival data were calculated.<bold>Results: </bold>The 5-year overall survival rates were significantly different between patients with ESS, LMS, and UES and MMMT (86 vs. 40 vs. 57 vs. 45 %; P < 0.001). The multivariate analysis showed that the patients' age, higher FIGO stage (III-IV), a history of smoking, prior pelvic radiation, diabetes, and residual tumor after surgery were associated with a poorer overall survival. Histological subtypes of LMS (HR 4.68; 95 % CI 1.35-16.17), UES (HR 1.21; 95 % CI 0.26-5.77) and MMMT (HR 1.63; 95 % CI 0.42-6.43) were also associated with a poorer overall survival than ESS (P = 0.008). Adjuvant therapies showed no associations with overall survival.<bold>Conclusions: </bold>Adjuvant therapy has so far not shown any overall survival benefit, and the focus is therefore on primary surgery. In future studies, the entities should be investigated separately in relation to prognostic factors and effective therapeutic management.
- Subjects
SARCOMA; MULLERIAN ducts; LEIOMYOSARCOMA; ADJUVANT treatment of cancer; DIABETES; CANCER cells; COMBINED modality therapy; MULTIVARIATE analysis; PROGNOSIS; SURVIVAL; UTERINE tumors; PROPORTIONAL hazards models; ENDOMETRIAL tumors; KAPLAN-Meier estimator; TUMOR treatment; THERAPEUTICS; CANCER treatment
- Publication
Archives of Gynecology & Obstetrics, 2016, Vol 294, Issue 2, p343
- ISSN
0932-0067
- Publication type
journal article
- DOI
10.1007/s00404-015-3993-6